Leeds Dialysis is a medicare approved dialysis facility center in Leeds, Alabama and it has 10 dialysis stations. It is located in Jefferson county at 1650 Maxey Drive, Leeds, AL, 35094. You can reach out to the office of Leeds Dialysis at (205) 699-5383. This dialysis clinic is managed and/or owned by Davita. Leeds Dialysis has the following ownership type - Profit. It was first certified by medicare in February, 2012. The medicare id for this facility is 012652 and it accepts patients under medicare ESRD program.
| Name | Leeds Dialysis |
|---|---|
| Location | 1650 Maxey Drive, Leeds, Alabama |
| No. of Dialysis Stations | 10 |
| Medicare ID | 012652 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1650 Maxey Drive, Leeds, Alabama, 35094 | |
| (205) 699-5383 | |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
| NPI Number | 1679857742 |
| Organization Name | Leeds Dialysis |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 1650 Maxey Dr Leeds, Alabama, 35094 |
| Phone Number | (205) 699-5383 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 17 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 18 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 41 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 355 |
| Percentage of adult patients getting regular hemodialysis at the center | 92 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Leeds Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 42 |
| Hypercalcemia patient months | 361 |
| Patients with Serumphosphor | 44 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 15 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 37 |
| Patient months included in arterial venous fistula and catheter summaries | 231 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 71 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 32 |
| Hospitalization Rate in facility | 191.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 428.6 |
| Hospitalization Rate: Lower Confidence Limit | 91.2 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Leeds Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 43.8 |
| Readmission Rate: Lower Confidence Limit | 10.7 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Leeds Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.18 (As Expected) |
| SIR: Upper Confidence Limit | 3.9 |
| SIR: Lower Confidence Limit | .2 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Leeds Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 29 |
| Transfusion Rate in facility | 57.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 220 |
| Transfusion Rate: Lower Confidence Limit | 17.9 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Leeds Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 148 |
| Mortality Rate in facility | 25.2 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 36.9 |
| Mortality Rate: Lower Confidence Limit | 16.4 |
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago
News Archive
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.
Should parents be able to use medical means to restrict the growth of profoundly disabled children to make them easier to care for at home. A working group convened to discuss the ethical and policy considerations of "growth attenuation" proposes some guidelines in an article in the Hastings Center Report. Personal essays including those of parents whose children cannot walk or speak accompany the article
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
As many as 30% of people with drug-resistant tuberculosis can be successfully treated with first-line drugs, Paul van Helden of the University of Stellenbosch's Center of Excellence for Biomedical TB Research said recently while presenting research on drug-resistant TB at a TB symposium in Maputo, Mozambique, Africa Science News Service reports.
› Verified 6 days ago